Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PolyA RNA-seq from liposarcoma cells treated with Nutlin3R and/or Carfilzomib

ABSTRACT: PolyA RNA-seq from liposarcoma cells treated with Nutlin3R and/or Carfilzomib

PROVIDER: PRJNA940486 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23692307_1.fastq.gz	Fastqsanger.gz
	SRR23692307_2.fastq.gz	Fastqsanger.gz
	SRR23692308_1.fastq.gz	Fastqsanger.gz
	SRR23692308_2.fastq.gz	Fastqsanger.gz
	SRR23692309_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

PolyA RNA-seq from liposarcoma cells treated with Nutlin3R and/or Carfilzomib

Project description:Analysis of steady-state mRNA levels in liposarcoma cells treated for 28 hr with 0.05% DMSO or 10 uM Nutlin3R and/or 12.5 nM Carfilzomib

2023-05-12 | GSE226530 | GEO

PolyA RNA-seq from liposarcoma cells treated with Nutlin3R

Project description:PolyA RNA-seq from liposarcoma cells treated with Nutlin3R

| PRJNA887473 | ENA

PolyA RNA-seq from liposarcoma cells treated with Nutlin3R

Project description:Analysis of steady-state mRNA levels in liposarcoma cells treated for 16 hr with 0.05% DMSO or 10 uM Nutlin3R

2023-05-12 | GSE214889 | GEO

Expression data from doxorubicin-treated Myxoid Liposarcoma cells and untreated control cells

Project description:Despite an improved survival of myxoid liposarcoma (MLS) patients, existing therapies have shortcomings including therapy resistance. To study the characteristics of therapy resistance in MLS, we treated three MLS cell lines with the commonly used chemotherapy drug doxorubicin and compared their gene expression profiles with untreated control cells.

2018-02-23 | GSE110997 | GEO

polyA-RNA-seq from mESC treated with doxorubicin

Project description:polyA-RNA-seq from mESC treated with doxorubicin

| PRJNA627712 | ENA

Secondary proteasome inhibitor carfilzomib resistant myeloma cell lines

Project description:Modulation of the activity of the ubiquitin-proteasome pathway with the proteasome inhibitor (PI) is an established component of therapy for plasma cell disorders. However, resistance emerges and the mechanism is incompletely understood. We generated carfilzomib-resistant (CR) myeloma cell lines by exposing drug-naive ANBL-6, KAS-6/1, U266, and OPM-2 cells to increasing concentrations of carfilzomib and then performed gene expression profiling (GEP) to identify prominent changes compared to their vehicle-treated counterparts, followed by exploration of the mechanism(s) of proteasome inhibitor resistance.

2016-10-09 | GSE62237 | GEO

Comparison of the gene expression profiles of carfilzomib-resistant derivatives versus parental human myeloma cell lines

Project description:KMS-11 and KMS-34 cells were exposed to stepwise increasing concentrations of carfilzomib over a period of 18 weeks: cells adapted to growth in 4 nM carfilzomib by 4 weeks, in 6 nM in another 6 weeks and in 12 nM after a further 8 weeks. The resulting cell cultures, denoted KMS-11/Cfz and KMS-34/Cfz, respectively, retained resistance to carfilzomib even when tested after removal of selective pressure for approximately 8 weeks. KMS-11/Cfz and KMS-34/Cfz cells were profiled for gene expression after 1 week of growth in the absence of carfilzomib together with parental KMS-11 and KMS-34 cells which had not been selected in the drug (triplicate samples).

2015-07-09 | E-GEOD-69078 | biostudies-arrayexpress

Comparative expression analysis of carfilzomib-resistant and parental LP-1 human multiple myeloma cells

Project description:LP-1 cells were exposed to stepwise increasing concentrations of carfilzomib over a period of 18 weeks: cells adapted to growth in 4 nM carfilzomib by 4 weeks, in 6 nM in another 6 weeks and in 12 nM after a further 8 weeks. The resulting cell culture, denoted LP-1/Cfz, retained resistance to carfilzomib even when tested after removal of selective pressure for approximately 8 weeks.

2016-09-13 | GSE78069 | GEO

Carfilzomib inhibits the progression of hepatocellular cancer via upregulating GADD45a expression

Project description:Hepatocellular carcinoma (HCC) ranks among one of the most prevalent and lethal cancers affecting humans. Currently, there are limited effective treatments available for HCC. In the search for potential anti-HCC agents, we found that carfilzomib, a proteasome inhibitor, exerts anti-HCC activities. However, the underlying mechanisms of action are main unclear. In this study, we evaluated the effectiveness of carfilzomib against HCC capability and explored its underlying mechanisms. Cell Counting Kit 8 (CCK8), EdU (5-ethynyl-2-deoxyuridine) staining, and colony formation assays were employed to analyze the antiproliferative ability of carfilzomib on MHCC-97H and Huh7 cells. Additionally, flow cytometry was used to assess the effect on the cell cycle. Western blotting was utilized to examine the protein expression levels associated with cell cycle arrest. Furthermore, short hairpin RNA (shRNA) transfection was used to investigate the role of GADD45a (growth arrest and DNA damage 45a) on carfilzomib-induced cell cycle arrest. A xenograft tumor model using nude mouse was employed to evaluate the anti-HCC activity of carfilzomib in vivo. The finding demonstrated that carfilzomib inhibited the proliferation, invasion, and migration in both MHCC-97H and Huh7 cells. In addition, carfilzomib caused cell cycle arrest by suppressing the expression of cyclin A1, cyclin E1, cyclin-dependent kinases 2 (CDK2), and cyclin-dependent kinases 4 (CDK4). It also upregulated the expression of GADD45a, and inhibition of GADD45a through shRNA abolished carfilzomib-induced cell cycle arrest in HCC cells. Importantly, carfilzomib demonstrated its ability to inhibit the Huh7 cell growth in vivo. Our research has revealed, for the first time, that carfilzomib inhibited the progression of HCC cells by upregulating GADD45a expression. These findings suggest that carfilzomib could be a potential chemotherapeutic agent against HCC.

2024-12-18 | GSE284346 | GEO

Expression data from doxorubicin-treated Myxoid Liposarcoma cells and untreated control cells

Project description:Expression data from doxorubicin-treated Myxoid Liposarcoma cells and untreated control cells

| PRJNA435553 | ENA